PRINCETON, N.J., Jan. 10 /PRNewswire/ -- Novo Nordisk, the world’s leading diabetes care company, today announced the appointment of Nathaniel Clark, M.D., as senior medical advisor in the company’s U.S. diabetes division. In this newly created position, Dr. Clark will provide medical leadership for key Novo Nordisk programs designed to improve patient outcomes.
Dr. Clark most recently served as vice president for clinical affairs at the American Diabetes Association (ADA), working closely with leading healthcare organizations as well as federal agencies such as the U.S. Department of Health and Human Services and the Centers for Disease Control. This experience will serve Dr. Clark in his role at Novo Nordisk, where he will provide medical leadership as an advisor for such initiatives as the company’s National Changing Diabetes Program, the DAWN Youth Program, and other partnership and association initiatives.
“Dr. Clark comes to Novo Nordisk with an extensive background in both clinical guidelines and healthcare policy,” said Alan Moses, M.D., associate vice president of medical affairs, Novo Nordisk. “We at Novo Nordisk are fortunate to have someone of Dr. Clark’s caliber to help convert our passion for changing diabetes into programs and approaches that will fulfill the needs of healthcare providers for the benefit of people with diabetes.”
“I share Novo Nordisk’s commitment to changing diabetes and look forward to taking part in its efforts to improve the experience and treatment of people living with the disease,” said Dr. Clark. “In my new role, I hope to ignite new energy to help advance the company’s innovative diabetes programs.”
Prior to the ADA, Dr. Clark joined the Joslin Diabetes Satellite Clinic on Cape Cod, where he served as associate director of diabetes services and director of pediatric services. He has worked as a staff endocrinologist in the Division of Endocrinology and in Pediatrics at the University of Vermont in Burlington and as director of the Vermont Regional Diabetes Center of Fletcher Allen Health Care.
Well-versed in the intricacies of diabetes care, Dr. Clark also holds a Master’s degree in nutrition and became a registered dietitian prior to graduating with a medical degree from the University of Massachusetts Medical School. He completed a combined pediatric and internal medicine residency at Baystate Medical Center in Springfield, Massachusetts, where he remained as an endocrinology fellow.
Novo Nordisk is a healthcare company with an 83-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk, photodesk@prnewswire.comNovo Nordisk
CONTACT: Media - Susan Jackson, +1-609-919-7776; or Investors - MadsVeggerby Lausten, +1-609-919-7937, both of Novo Nordisk
